Hypertension

Scene Health and CareFirst Expand Partnership for Medicaid Members

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Professional Services, Managed Care, Other Health, Health, General Health, Pharmaceutical, Health Insurance, Infectious Diseases, Insurance, Clinical Trials, Culture, Johns Hopkins, Entrepreneurship, Partnership, CareFirst BlueCross BlueShield, Patient, Prescription, Asthma, Quality, Medicaid, Multimedia, Medicine, Hypertension, Pharmaceutical industry

Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.

Key Points: 
  • Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.
  • “Our partnership with Scene has helped deepen our understanding of the real-life experiences and challenges members were facing,” said Mike Rapach, President and CEO of CareFirst Community Health Plan Maryland (CHPMD).
  • “We are grateful for five years of outstanding partnership with CareFirst BlueCross BlueShield of Maryland’s Medicaid team.
  • “Innovations such as Scene Health's services seamlessly coordinated with other CareFirst health services, benefits, and rich network coverage are critical for us to improve the overall health and quality of care for our members."

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Retrieved on: 
Wednesday, March 20, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Clinical Trials, Q&A, Medication, Webcast, Alnylam Pharmaceuticals, Angiotensin, American College, RNA interference, Therapy, AGT, ACC, Cardiomyopathy, Hypertension

The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.

Key Points: 
  • The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.
  • A replay of the call will be available two hours after the call and archived on the same webpage for six months.
  • A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events .
  • An archived webcast will be available on the Company’s website approximately two hours after the event.

Taste Modulators Market Analysis by Type (Sweet Modulators, Salt Modulators, Fat Modulators), Application (Food, Beverages, Pharmaceutical) - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Technology, Retail, Food Tech, Food, Beverage, Health, Module (mathematics), Tate & Lyle, Government, Taste, Growth, Market development, Row, DSM, Research, Increase, Investment, Snack, PAMS, USD, Medicine, Hypertension, Extensive, Renewable energy

The "Global Taste Modulators Market by Type (Sweet Modulators, Salt Modulators, Fat Modulators), Application (Food, Beverages, Pharmaceutical), and Region (North America, Europe, Asia-Pacific, South America, RoW) - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Taste Modulators Market by Type (Sweet Modulators, Salt Modulators, Fat Modulators), Application (Food, Beverages, Pharmaceutical), and Region (North America, Europe, Asia-Pacific, South America, RoW) - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The adaptability of salt modulators across diverse food applications, ranging from snacks to processed foods, further solidifies their market dominance.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the Taste Modulators market.
  • The report also helps stakeholders understand the Taste Modulators market and provides them with information on key market drivers, restraints, challenges, and opportunities.

CopilotIQ Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Cardiology, Software, General Health, Health, Diabetes, Artificial Intelligence, Health Technology, Technology, Blood pressure, Glucose, Editorial, Culture, Organization, Entrepreneurship, MIC, Physician, Biomarker, AI, Hope, Anomaly, Fasting, Hyperglycemia, ITunes, Most, Medicare, BMI, Nursing, Medicare Advantage, Hypertension, Human, Pharmaceutical industry

CopilotIQ , the company reshaping care for older Americans with diabetes and hypertension, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.

Key Points: 
  • CopilotIQ , the company reshaping care for older Americans with diabetes and hypertension, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.
  • Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

Anthem Blue Cross and Blue Shield Foundation Awards $11 Million to Community Partners in New York

Retrieved on: 
Friday, March 15, 2024
Women, Other Philanthropy, Seniors, Men, General Health, Consumer, Food, Beverage, People with Disabilities, Retail, Mental Health, Parenting, Baby, Maternity, Health Insurance, Fitness & Nutrition, LGBTQ+, Philanthropy, Alternative Medicine, Health, Fund Raising, Foundation, Vitamins, Supplements, Well, BIPOC, American Heart Association, Culture, Conditional sentence, Organization, Food bank, Risk, Diabetes, Suds, City, Mental health, FAM, Elevance Health, Pregnancy, Woman, Partnership to End Addiction, New Yorker, 2005 in television, Blue Shield, Maternal health, Addiction, Hypertension, MHA, Clifford Whittingham Beers, Pharmaceutical industry

Anthem Blue Cross and Blue Shield Foundation continued its critical work to measurably improve health and strengthen local communities in 2023.

Key Points: 
  • Anthem Blue Cross and Blue Shield Foundation continued its critical work to measurably improve health and strengthen local communities in 2023.
  • “Our Foundation strives to improve the health of humanity by addressing health inequities and strengthening our communities in New York.
  • Our strategy underscores this commitment by focusing on partnerships and programs that aid the health of the socially vulnerable,” said Victor DeStefano, President of Anthem Blue Cross and Blue Shield in New York.
  • Other Anthem Blue Cross and Blue Shield Foundation grant recipients last year included: American Heart Association, Project Renewal, Gay Men’s Health Crisis, Community Access, and Tent Ministries.

Welldoc Announces CE Mark Certification

Retrieved on: 
Tuesday, March 12, 2024
Software, Mobile, Wireless, Apps, Applications, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, FDA, Health, Diabetes, CE, Certification, Hypertension, AI, Medical device

Welldoc, a leading digital health company specializing in cardiometabolic health, today announced that its flagship BlueStar® mobile app has received CE mark certification as a Class IIa medical device under the European Union Medical Device Regulation (EU-MDR).

Key Points: 
  • Welldoc, a leading digital health company specializing in cardiometabolic health, today announced that its flagship BlueStar® mobile app has received CE mark certification as a Class IIa medical device under the European Union Medical Device Regulation (EU-MDR).
  • This significant achievement allows Welldoc to apply the CE mark to their medical device software.
  • “We are thrilled to receive the CE mark certification,” said Kevin McRaith, President and CEO at Welldoc.
  • The CE mark certification indicates that Welldoc’s digital health solution meets stringent safety, performance and quality standards established by the EU for Class IIa medical devices.

Global Guidewires (Nitinol, Stainless Steel, Others) Market Report 2024: Analysis & Forecasts 2019-2022 and 2023-2029 - Minimally Invasive Techniques Expand, Boosting Guidewire Utilization - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Medical Supplies, Medical Devices, Disease, PVI, Friction, ERCP, Coronary artery disease, Conditional sentence, Bacteria, Epidemiology, Specialization, Risk, Investment, Infection, Patient safety, USD, Surgery, Non-communicable disease, Cardiovascular disease, Fungal infection, Obesity, Biotechnology, Peripheral artery disease, Porter's five forces analysis, Diabetes, Chlorhexidine, World Health Organization, Safety, Fatigue, Hypertension, Cardiology, Neurology, Urology, Prevalence, Death, PCI, Diagnosis, Arrhythmia, Temperature, Growth, Incidence, Anatomy, SWOT, Mortality, Stainless steel, WHO, Nickel titanium, Physician, Medical imaging

Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.

Key Points: 
  • Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.
  • As the prevalence of risk factors such as obesity, diabetes, and hypertension increase, so does the incidence of cardiovascular diseases.
  • Guidewires are essential tools in percutaneous coronary interventions (PCI), peripheral vascular interventions (PVI), and electrophysiology procedures, driving the demand for guidewires.
  • The increasing prevalence of chronic diseases worldwide drives the demand for guidewires by necessitating minimally invasive interventions for diagnosis and treatment.

Fifty-Five Percent of Hypertension Patients Said They Have Issues Sending Results from Bluetooth®-Connected Blood Pressure Monitors

Retrieved on: 
Monday, March 11, 2024
Health, Medical Devices, Technology, Practice Management, Health Technology, Mobile, Wireless, Cardiology, Blood pressure, Disease, Vital signs, Diabetes, Patient, Mayo Clinic, Switch, Smart meter, AT&T, Hypertension, RPM, Mobile phone

A majority of patients, however, have issues sending their readings to a healthcare professional when using remote monitoring systems that require Bluetooth®-connected devices, apps, and hubs.

Key Points: 
  • A majority of patients, however, have issues sending their readings to a healthcare professional when using remote monitoring systems that require Bluetooth®-connected devices, apps, and hubs.
  • Only about 25% of people with hypertension have their condition under control, according to the Centers for Disease Control and Prevention1 and the Mayo Clinic lists home monitoring as a key factor in helping patients control their blood pressure.
  • In the 2024 National Hypertension Survey, 55% of respondents said they have some type of issue sending their reading when using a Bluetooth-enabled blood pressure monitor.
  • And 30% said they always have an issue, which is a significant increase from the 8% in the 2023 National Hypertension Survey.

Empowering Change: AMCP Foundation partners with Moda Health and Novo Nordisk Inc., launching a Health Disparities Research Internship

Retrieved on: 
Wednesday, April 3, 2024
Pharmacist, Health, Doctor of Pharmacy, Health equity, Partnership, Diabetes, Howard University, Knowledge, Regression analysis, Research, Moda Health, Walker, Chronic kidney disease, Geography, Hypertension, Collection, Medicine, Assistant director, Nursing

Sinclair brings a wealth of knowledge and a passion for health care research with a keen interest in addressing health disparities.

Key Points: 
  • Sinclair brings a wealth of knowledge and a passion for health care research with a keen interest in addressing health disparities.
  • The collaboration among AMCP Foundation and intern alumni Carly Rodriguez, PharmD, FAMCP VP & Chief Pharmacy Officer, Moda Health, and Courtney Walker, PharmD, RPh, Medical Account Director – Employers West, Novo Nordisk Inc. represents a critical alliance in health disparities research, focusing on unveiling insights into medication adherence disparities.
  • This strategic partnership exemplifies the synergy essential for impactful research, emphasizing a collective commitment to addressing health disparities.
  • In her unique role, Sinclair is at the forefront of research addressing health disparities related to GLP-1s, medications crucial in diabetes treatment.